Boosting Investment in R&I: €100,000 donation by kENUP Foundation to Malta’s COVID-19 R&D Fund
1.8.2020 11:23:00 EEST | Business Wire | Press release
kENUP Foundation has presented €100,000 donation into Malta’s COVID-19 R&D Fund. The Fund is managed jointly by the Malta Council for Science and Technology (MCST) and Malta Enterprise with the support of the Ministry for Finance and Financial Services, and the Ministry for the Economy, Investment & Small Businesses. The Malta fund will see €5.3M funnelled into developing innovative and improved scientific and technological approaches to the challenges raised by COVID-19 and future pandemics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200801005005/en/
Boosting Investment in R&I: €100,000 donation by kENUP Foundation to Malta’s COVID-19 R&D Fund (Photo: Business Wire)
kENUP, a Malta-based not-for-profit global partnership in innovation, promotes research-based innovation for Europe with public and societal benefit. Holm Keller, Chairman of kENUP Foundation said, “We are very grateful to the Maltese Government for the initial support in the setting up of the Foundation in the Republic of Malta. kENUP Foundation is supporting the provision of financing for companies engaged in the development of innovative products aimed at fighting COVID-19. We are therefore very happy to also contribute to the Maltese COVID-19 R&D Fund and to support projects designed to protect the Maltese people and beyond."
“With this significant donation, kENUP is giving the Malta Council for Science and Technology its appreciated support by boosting the Euro 5.3 Million COVID-19 R&D Fund set up using central government funding earlier this year,” said Dr Jeffrey Pullicino Orlando, Executive Chairman of the Malta Council for Science and Technology.
In his keynote speech, Parliamentary Secretary for Financial Services and Digital Economy Hon. Clayton Bartolo said that Malta is not a newcomer to kENUP initiatives. “I know that years ago, MCST envisioned that kENUP could truly bring something new and big to Malta’s ailing research and innovation sector. Along the years, kENUP has also found this government’s help in addressing legal issues allowing for a novel concept in online tertiary education which ultimatley led to this setting up of EDU, also in Malta.”
The Parliamentary Secretary also highlighted that six years from its inception, kENUP has solidly established itself globally in innovation support particularly in the health sector. “Through this donation our country will strengthen its cause for more investment in Research & Development,” remarked Hon. Bartolo.
The video of the event can be found at https://www.covidx.eu/news/#Malta
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200801005005/en/
Contact information
Press contacts:
kENUP covidX Programme: Nadine Castillo tel: +356 99452436
MCST COVID-19 R&D fund: Giselle Calleja tel: +356 2360 2173
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors9.9.2026 16:45:00 EEST | Press release
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) today announced that Dr. Kunihiro Hattori (former Senior Fellow of Chugai), Dr. Takehisa Kitazawa (Deputy Head of Research Division, Chugai), and Dr. Tomoyuki Igawa (Head of Research Division, Chugai), who led the creation of Hemlibra (emicizumab), a treatment for hemophilia A, have been awarded the Lasker-DeBakey Clinical Medical Research Award, one of the world's most prestigious scientific honors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909923883/en/ From left: Dr. Kitazawa, Dr. Hattori, and Dr. Igawa Hemophilia A is caused by a deficiency of coagulation Factor VIII, one of the proteins required for normal blood clotting. When activated, Factor VIII serves as a bridge that facilitates the activation of Factor X by activated Factor IX on the surface of activated platelets. The award recognizes the unconventional concept of replacing this function of Factor VIII with a
AMCS Appoints Richard Humphrey as Chief Product and Technology Officer9.9.2026 16:00:00 EEST | Press release
AMCS, a leading technology provider for the waste and recycling industry, today announced the appointment of Richard Humphrey as Chief Product and Technology Officer. Based in Boston, Humphrey will lead the company’s global product organisation. Humphrey brings more than 25 years of experience developing software for construction and other complex industrial environments. He joins AMCS as the company deepens its focus on waste and recycling and expands the role of AI across its platform. Most recently, Humphrey served as Chief Product and Technology Officer at Contruent, where he led product strategy for a construction cost-management platform used on major capital programmes. He previously held vice president roles at Bentley Systems and B2W Software. Earlier in his career, he spent more than a decade at Autodesk, where he led its Civil Design and Construction software business as Senior Director. “Richard understands what it takes to build software for industries where the work is ex
BBH Launches a New Technology Business, Braid, Solving for Intelligent Data Transformation9.9.2026 15:45:00 EEST | Press release
Brown Brothers Harriman (BBH) today announced the launch of a new technology affiliate, Braid LLC, focused on solving enterprise data transformation for financial services. Braid offers an AI-native data transformation platform that gives firms a scale solution to transform, connect, and manage their data with confidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909294398/en/ Braid empowers teams to build, automate, and oversee reliable production-grade data transformations in a fraction of the time typically required today. Instead of requiring engineers to build data automations, Braid allows business users to describe their needs in natural language that AI agents use to build intelligent data transformations that are transparent and fully auditable. Braid’s enterprise-grade engine then processes and delivers those data transformations in a controlled and deterministic environment. Built by financial services exp
LTM Collaborates with IBM and Red Hat on Lightwell to Advance AI-Driven Open-Source Software Remediation9.9.2026 15:30:00 EEST | Press release
LTM, the Business Creativity partner to the world's largest enterprises, today announced that it has collaborated with IBM and Red Hat on Lightwell to help enterprises safeguard the open-source software supply chain through AI-driven vulnerability remediation. As AI accelerates the discovery of software vulnerabilities, organizations must move beyond detection-focused approaches and adopt enterprise-scale remediation strategies that enable rapid risk mitigation without disrupting business-critical applications. Lightwell’s approach of delivering validated fixes for production environments aligns with LTM's aim of helping customers build secure, resilient, and operationally efficient software supply chains. By combining AI-powered remediation capabilities with enterprise-grade validation and deployment support, Lightwell aims to help organizations address security challenges across increasingly complex open-source ecosystems. Building on its long-standing status as an IBM Platinum Partn
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life9.9.2026 15:24:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).1 Oveporexton is the first and only medicine to treat the underlying cause of NT1. "People living with narcolepsy type 1 face persistent symptoms across the day and night, which can impact many aspects of daily life,” said Emmanuel Mignot, M.D., Ph.D., principal investigator for the FirstLight (TAK-861-3001) Phase 3 study. “The newly published Phase 3 data reinforce the potential of oveporexton to transform how we approach narcolepsy type 1 in clinical practice, shifting from managing individual symptoms to treating the disease itself.” NT1 is a chronic, rare neurological disease driven by orexin deficiency. As a result, people experience a range of daytime and nighttime symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom